A Long-Term Prospective Evaluation of the Predictive Value of Molecular Markers in Serum and Cerebrospinal Fluid in Patients in the Early Stage of Multiple Sclerosis.

Mariola Świderek-Matysiak, Magdalena Oset, Karolina Pendrasik, Dominika Świerczewska, Małgorzata Domowicz, Magdalena Namiecińska, Mariusz Stasiołek

Abstract read

PubMed Full text at PMC Publisher

In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mariola Świderek-MatysiakDepartment of Neurology, Medical University of Lodz, Kosciuszki Street 4, 90-419 Lodz, Poland.ORCID 0000-0002-6779-308X

Magdalena OsetDepartment of Neurology, Medical University of Lodz, Kosciuszki Street 4, 90-419 Lodz, Poland.

Karolina PendrasikDepartment of Neurology, Medical University of Lodz, Kosciuszki Street 4, 90-419 Lodz, Poland.

Dominika ŚwierczewskaDepartment of Neurology, Medical University of Lodz, Kosciuszki Street 4, 90-419 Lodz, Poland.

Małgorzata DomowiczDepartment of Neurology, Medical University of Lodz, Kosciuszki Street 4, 90-419 Lodz, Poland.ORCID 0000-0002-7804-9926

Magdalena NamiecińskaDepartment of Immunogenetics, Medical University of Lodz, Kosciuszki Street 4, 90-419 Lodz, Poland.ORCID 0000-0002-6874-4992

Mariusz StasiołekDepartment of Neurology, Medical University of Lodz, Kosciuszki Street 4, 90-419 Lodz, Poland.ORCID 0000-0002-2582-1708

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Various molecular biomarkers have been suggested as a method to improve the predictive value of prognosis in multiple sclerosis (MS). The characterization of such biomarkers would greatly enhance individual patient management. The aim of this study was to conduct a long-term, prospective evaluation of the prognostic value of molecular biomarkers in serum and cerebrospinal fluid (CSF) in patients in the early stages of MS, before the first treatment initiation. The study included a total of 121 MS patients. Serum and CSF were obtained during diagnostic process. Concentrations of IFN

Indexed as

BiomarkersMultiple SclerosisAdultChemokine CXCL13FemaleGlial Fibrillary Acidic ProteinHumansInterleukin-6MaleMiddle AgedNeurofilament ProteinsOsteopontinPrognosisProspective StudiesBiomarkersChemokine CXCL13CXCL13 protein, humanGlial Fibrillary Acidic ProteinInterleukin-6neurofilament protein LNeurofilament ProteinsOsteopontinbiomarkersinterleukin 6multiple sclerosisneurofilamentsprognosis

Identifiers

PMID41977341

DOI10.3390/ijms27073155

PMCPMC13073961

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.